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Abstract of the paper 
 
Tatsuya Isomura 
 
Title: Liver-related safety assessment of green tea extracts in humans: a systematic 
review of randomized controlled trials 
Objective: There remain liver-related safety concerns, regarding potential 
hepatotoxicity in humans, induced by green tea intake, despite being supposedly 
beneficial. Although many randomized controlled trials (RCTs) of green tea extracts 
have been reported in the literature, the systematic reviews published to date were only 
based on subjective assessment of case reports. To more objectively examine the 
liver-related safety of green tea intake, we conducted a systematic review of published 
RCTs.  
Methods: A systematic literature search was conducted using three databases (PubMed, 
EMBASE and Cochrane Central Register of Controlled Trials) in December 2013 to 
identify RCTs of green tea extracts. Data on liver-related adverse events, including 
laboratory test abnormalities, were abstracted from the identified articles. 
Methodological quality of RCTs was assessed.  
Results: After excluding duplicates, 561 titles and abstracts and 119 full-text articles 
were screened, and finally 34 trials were identified. Of these, liver-related adverse 
events were reported in four trials; these adverse events involved seven subjects (eight 
events) in the green tea intervention group and one subject (one event) in the control 
group. The summary odds ratio, estimated using a meta-analysis method for sparse 
event data, for intervention compared with placebo was 2.1 (95% confidence interval: 
0.5–9.8). The few events reported in both groups were elevations of liver enzymes. Most 
were mild, and no serious liver-related adverse events were reported.  
Conclusion: Results of this review, although not conclusive, suggest that liver-related 
adverse events after intake of green tea extracts are expected to be rare. 
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